Related Experiment Video
Updated: May 25, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
MicroRNAs in Alzheimer's disease
Charlotte Delay1, Wim Mandemakers, Sébastien S Hébert
1Centre de Recherche du CHUQ, Axe Neurosciences, Quebec City, Quebec, Canada G1V4G2.
Neurobiology of Disease
|January 31, 2012
Summary
MicroRNAs (miRNAs) are implicated in Alzheimer's disease (AD) risk. Dysregulated miRNAs affect key AD genes like APP and BACE1, suggesting their crucial role in neurodegeneration and dementia.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alzheimer's disease (AD) is a leading cause of dementia in older adults.
- MicroRNAs (miRNAs) are small non-coding RNAs vital for neuronal function and gene regulation.
- Evidence suggests miRNA network alterations contribute to AD pathogenesis.
Purpose of the Study:
- To review current findings on miRNA research in Alzheimer's disease.
- To explore the role of miRNAs in AD pathophysiology across human, cellular, and animal models.
- To provide a foundation for future research into miRNAs and AD.
Main Methods:
- Review of existing human profiling experiments.
- Analysis of miRNA regulation in cellular and animal models of AD.
- Examination of genetic polymorphisms in miRNA target sites.
Main Results:
- Specific miRNAs are misregulated in AD conditions.
- These miRNAs target key genes implicated in AD, such as APP, BACE1, and MAPT.
- Disease-specific polymorphisms in miRNA target sites of APP and BACE1 have been identified.
Conclusions:
- miRNA dysregulation is a significant factor in Alzheimer's disease.
- miRNAs represent potential therapeutic targets for AD.
- Further research is warranted to fully elucidate the contribution of miRNAs to AD pathophysiology.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...